Our Science | ALK

Our science

With 100+ years of experience in pioneering allergy treatment, nobody knows allergy like us.
Links
Scientific focus
Science & technology
Pipeline
Digital innovation
Clinical data sharing
Collaboration & partnerships
Healthcare Professionals

At the core of ALK, innovation thrives. We have spent the past 100+ years pioneering within the field of allergy with the continued purpose of helping more people living with allergy.

Our deep understanding of the underlying biology and how allergy works has given us the foundation to develop a range of allergy immunotherapy treatments and management options, forming the core of our current product range. We remain committed to advancing science and are dedicated to innovate and expand our Research & Development (R&D) pipeline, continuously providing novel concepts within allergy research and treatment.

Our scientific focus is centered around respiratory allergy, food allergy, anaphylaxis and adjacent diseases areas.

Our scientific focus areas

Our scientific focus is to advance science and identify biological pathways to lead discovery and development of innovative medicines within allergy and adjacent therapy areas. We are implementing cutting-edge technologies and new data platforms to accelerate our drug discovery pipeline and transform how we work across R&D. Our mission is to improve the lives of people living with allergy.


Respiratory allergy 

Read more

Food allergy

Read more

Anaphylaxis

Read more

Adjacent therapy areas 

Read more
Image description
Respiratory allergy

Over 500 million people globally live with allergic rhinitis (AR), and despite symptom-relieving treatment, many live with an uncontrolled disease.

Early intervention is key to addressing the progression of allergic diseases, including the atopic march.

At ALK, we remain committed to advancing science in respiratory allergy. We will continue to strengthen our leadership in allergy immunotherapy and have a strong focus on disease modification and prevention of allergic co-morbidities.

Our translational research seeks to uncover methods for preventing allergic asthma as well as to assess how environmental elements including viruses and genetic variables may impact the progression of asthma and the effectiveness and tolerability of treatment options.

Our pipeline

Image description
Food allergy

Food allergy is a potentially life-threatening disease with increasing prevalence in many regions. Currently affecting an estimated 4% of all children worldwide.

For people living with this disease, exposure to certain foods can lead to anaphylaxis, a potentially life-threatening condition that requires immediate medical attention. Peanut allergy is one of the food allergies leading to the highest rates of anaphylaxis.

ALK is building a presence in peanut allergy, and we are determined to advancing the science to help people with food allergies.

Drawing on a century of expertise in allergy medicine, we are dedicated to developing innovative treatments for food allergy through immunology research. Our research aims to explore innovative therapies that may modify the course of food allergies and improve patient outcomes.

Our pipeline

Image description
Anaphylaxis

Anaphylaxis is a severe and acute allergic reaction that occurs when the immune system overreacts to a certain allergen. The health burden imposed by the risk of anaphylaxis can have a considerable impact on the quality of life for both patients and their relatives.

We aim to leverage our scientific legacy in severe allergies and remain dedicated to improving the lives of people at risk of anaphylaxis.

We strive to deliver new patient-friendly adrenaline administration solutions, designed for ease of use.

Our pipeline

Image description
New adjacent areas

We are founded in allergology and immunology and are leveraging our deep knowledge in ”Type 2” immune mechanisms and dysregulation with the ambition to discover new targets and develop improved solutions for people living with these complex allergic disorders.

Our team of scientists is committed to uncover new pathways and advance science within mast cells and IgE memory B-cells, both of which play pivotal roles in the allergic response.

Our goal is to explore treatments that aim to rebalance the immune system and improve patient outcomes.

Our pipeline

Our clinical pipeline

Our commitment to helping people and families living with the burden of allergy drives our discovery and development of innovative medicines addressing the unmet needs within allergy. With a strong foundation built on science and biology understanding, we are continuously advancing our pipeline to deliver novel solutions.

Our clinical pipeline is currently focused on researching and developing solutions within peanut allergy and anaphylaxis.

Explore our pipeline

Read more about our scientific focus areas.

Clinical trials

Information about our clinical trials can be found via the freely public registries clinicaltrialregister.eu, clinicaltrials.gov or on this page Clinical trials synopses.

Last updated: 15.11.2024